Access the full text.
Sign up today, get DeepDyve free for 14 days.
References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.
Overexpression of c-erbB-2 is seen in both infiltrating and in situ mammary carcinoma. In the former it has been associated with poor prognosis. Immunohistological demonstration of membrane staining of tumor cells is considered an acceptable means of identifying c-erbB-2 protein overexpression. A variety of antibodies to the c-erbB-2 molecule are now available for this purpose. We compared the sensitivity of five of the more commonly used antibodies (Dako c-erbB-2, 21N, CB11, C Neu, and CBE1) on a series of 24 cases of in situ ductal carcinoma of the breast. The incidence of positive membrane staining in tumour cells with the different antibodies ranged from 33% (21N and CBE1) to 46% (Dako and C Neu). These antibodies were further tested on pelleted, fixed, and processed cell lines (SKBR3, MCF7, and HLB100) with a known c-erbB-2 gene copy number. Correlation between the extent and strength of staining and gene copy number was demonstrated. Titration of antibodies against known standards is particularly important when the presence of staining is interpreted as a marker of prognosis. It also permits standardisation of results and validates comparisons of studies from different laboratories.
Applied Immunohistochemistry & Molecular Morphology – Wolters Kluwer Health
Published: Jan 1, 1996
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.